Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Caris Life Sciences (CAI) Gross Margin (2024 - 2025)

Caris Life Sciences has reported Gross Margin over the past 2 years, most recently at 84.93% for Q4 2025.

  • Quarterly results put Gross Margin at 84.93% for Q4 2025, up 1381.0% from a year ago — trailing twelve months through Dec 2025 was 79.88% (changed N/A YoY), and the annual figure for FY2025 was 79.37%, up 1639.0%.
  • Gross Margin for Q4 2025 was 84.93% at Caris Life Sciences, up from 80.97% in the prior quarter.
  • Over the last five years, Gross Margin for CAI hit a ceiling of 84.93% in Q4 2025 and a floor of 61.31% in Q2 2024.